Abstract
Introduction: Primary subclavian vein thrombosis (PSVT) is a rare (2/100.000/year) disorder, affecting predominantly young, healthy individuals. The disease can be idiopathic or effort-induced. The relative importance of risk factors for PSVT is not clarified, sex differences are mostly unknown. Studies show different incidence of idiopathic versus effort-induced PSVT. Aims: To investigate if risk factors differ between men and women with PSVT. The secondary aim was to examine differences regarding time from symptom to diagnosis and treatment between men and women. Material and Methods: 135 patients treated for PSVT in Stockholm county 2007-2017 was examined. Data on gender, age, weight, height, smoking, use of oral contraceptives, previous venous thrombotic events (VTE), family VTE, clotting disorders, were collected. Information on whether strenuous muscular activity preceded PSVT debut, and data on time variables where collected. Chi-2-test was used to evaluate differences in categorical data between men and women. Mann-Whitney U-test was used to evaluate time from symptom to first health care contact, diagnosis and treatment. One-way ANOVA was used to adjust for potential confounding variables for time data. Results: More men than women had effort-induced PSVT debut (p=0.006). Men had longer patient delay than women (p=0.064). The difference remained significant after adjustment for strenuous muscular activity. Conclusions: It was more common with effort-induced PSVT amongst men than women. Patient-delay was longer for men than women. Because of the study design, there was no control group, more research is needed to elucidate if causation is present. Keywords: Primary subclavian vein thrombosis, upper extremity deep vein thrombosis, Paget Schroetter syndrome, risk factors, gender differences
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Regional Ethics Committe of Stockholm County (Regionala Etikprovningsnaemnden i Stockholm) gave ethical approval for this work (Diary number 2016/2484-31/2)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos